Eli Lilly continues to emphasize the potential harm that could come with using GLP-1 receptor agonists for off-label purposes.
Beyond the Ordinary Beyond the Obvious
Beyond the Ordinary Beyond the Obvious
Eli Lilly continues to emphasize the potential harm that could come with using GLP-1 receptor agonists for off-label purposes.
